Formononetin Induces Apoptosis in PC-3 Prostate Cancer Cells Through Enhancing the Bax/Bcl-2 Ratios and Regulating the p38/Akt Pathway

REFERENCES

• Aparicio A and Logothetis CJ: Maity SN.Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 1, 466–468, 2011.
   PubMed Web of Science ®Google Scholar
• Paller CJ and Antonarakis ES: Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 11, 14–23, 2013.
   PubMedGoogle Scholar
• Baade PD, Youlden DR, and Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53, 171–184, 2009.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ward E, Brawley O, and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212–236, 2011.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Carducci MA, and Philips GK: Management of bone metastases in refractory prostate cancer—role of denosumab. Clin Interv Aging 7, 363–372, 2012.
   PubMed Web of Science ®Google Scholar
• Zhao E, Wang L, Dai J, Kryczek I, Wei S, et al.: Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 1, 152–161, 2012.
   PubMed Web of Science ®Google Scholar
• Gulati R, Gore JL, and Etzioni R: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 158, 145–153, 2013.
   PubMed Web of Science ®Google Scholar
• Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, et al.: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66, 811–821, 2012.
   Web of Science ®Google Scholar
• Yip K and Alonzi R: Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol 5, 25–34, 2013.
   Google Scholar
• Jia L, Ma S, Hou X, Wang X, Qased AB, et al.: The synergistic effects of traditional Chinese herbs and radiotherapy for cancer treatment. Oncol Lett 5, 1439–1447, 2013.
   PubMed Web of Science ®Google Scholar
• Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, et al.: Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 16, 1156–1166, 2009.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhao P, Niu J, Wang J, Cao Y, et al.: Research on phytoestrogenic effect of formononetin. Zhongguo Zhong Yao Za Zhi 35, 3060–3064, 2010.
   PubMedGoogle Scholar
• Chen J, Zeng J, Xin M, Huang W, and Chen X: Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res 43, 681–686, 2011.
   PubMed Web of Science ®Google Scholar
• Chen J and Sun L: Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells. Horm Metab Re. 44, 943–948, 2012.
   PubMed Web of Science ®Google Scholar
• Friedl P and Alexander S: Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992–1009, 2011.
   PubMed Web of Science ®Google Scholar
• Peters BG: An overview of chemotherapy toxicities. Top Hosp Pharm Manage 14, 59–88, 1994
   PubMedGoogle Scholar
• Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, et al.: CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258, 41–56, 2011.
   PubMed Web of Science ®Google Scholar
• Kwee SH, Tan HH, Marsman A, and Wauters C: The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo. Maturitas 58, 83–90, 2007.
   PubMed Web of Science ®Google Scholar
• Li XQ and Ling CQ: Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients: a systematic review and meta-analysis. Zhong Xi Yi Jie He Xue Bao 10, 1341–1362, 2012.
   PubMedGoogle Scholar
• Auyeung KK, Law PC, and Ko JK: Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. Oncol Rep 28, 2188–2194, 2012.
   PubMed Web of Science ®Google Scholar
• Moriyama-Gonda N, Sumi H, Yokogi H, and Ishibe T: Short-term incubation study on inhibitory effect of chemohyperthermia against hormone-independent human prostatic carcinoma cell line (PC-3). Gan To Kagaku Ryoho 19, 2201–2205, 1992.
   PubMedGoogle Scholar
• Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, et al.: Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate 72, 1648–1658, 2012.
   PubMed Web of Science ®Google Scholar
• Berridge MV, Herst PM, and Tan AS: Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11, 127–152, 2005.
   PubMedGoogle Scholar
• van Meerloo J, Kaspers GJ, and Cloos J: Cell sensitivity assays: the MTT assay. Methods Mol Biol 731, 237–245, 2011.
   PubMedGoogle Scholar
• Luo S and Rubinsztein DC: Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ 17, 268–277, 2010.
   PubMed Web of Science ®Google Scholar
• Kang MH and Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15, 1126–1132, 2009.
   PubMed Web of Science ®Google Scholar
• Bowen JM, Gibson RJ, Keefe DM, and Cummins AG: Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37, 56–62, 2005.
   PubMed Web of Science ®Google Scholar
• Park SJ, Park SH, Kim JO, Kim JH, Park SJ, et al.: Downregulation of KLF4 and the Bcl-2/Bax ratio in advanced epithelial ovarian cancer. Oncol Lett 4, 1033–1036, 2012.
   PubMed Web of Science ®Google Scholar
• Yoon O and Roh J: Downregulation of KLF4 and the Bcl-2/Bax ratio in advanced epithelial ovarian cancer. Oncol Lett 4, 1033–1036, 2012.
   PubMed Web of Science ®Google Scholar
• Trempolec N, Dave-CollN, and Nebreda AR: SnapShot: p38 MAPK Signaling. Cell 152, 656–656, 2013.
   PubMed Web of Science ®Google Scholar
• Han J and Sun P: The pathways to tumor suppression via route p38. Trends Biochem Sci 32, 364–371, 2007.
   PubMed Web of Science ®Google Scholar
• Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537–549, 2009.
   PubMed Web of Science ®Google Scholar